Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pramlintide (Amylin).

D Barlocco1

  • 1University of Milan, 1st Chimo Farmaceutico/Tossicologico, Italy. daniela.barlocco@unimi.it

Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Pramlintide, an amylin analog, is being developed as a diabetes treatment. Regulatory submissions are underway in the US and Europe for its use in type 1 and type 2 diabetes.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Designed multiple ligands: basic research vs clinical outcomes.

Current medicinal chemistry·2012
Same author

Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target.

Current medicinal chemistry·2008
Same author

Thymidylate synthase structure, function and implication in drug discovery.

Current medicinal chemistry·2005
Same author

Semicarbazide-sensitive amine oxidase: current status and perspectives.

Current medicinal chemistry·2004
Same author

Selective ACAT inhibitors as promising antihyperlipidemic, antiathero-sclerotic and anti-Alzheimer drugs.

Mini reviews in medicinal chemistry·2003
Same author

Characterization and pharmacological actions of tecostanine, an alkaloid of Tecoma stans.

Die Pharmazie·2003
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Pramlintide is a synthetic analog of human amylin.
  • It is being developed for diabetes management.

Purpose of the Study:

  • To evaluate pramlintide as an adjunct therapy with insulin for type 1 and type 2 diabetes.
  • To seek regulatory approval for marketing pramlintide.

Main Methods:

  • Submission of a US New Drug Application (NDA) to the FDA.
  • Submission of a Marketing Authorisation Application (MAA) to the EMEA.
  • Review by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee.

Main Results:

  • Amylin received an approvable letter from the FDA for both type 1 and insulin-using type 2 diabetes.
  • Discussions with the FDA are ongoing regarding required clinical work for NDA approval.

    • Conclusions:

    • Pramlintide shows potential for managing type 1 and type 2 diabetes.
    • Further clinical evaluation is required for full FDA approval.